Literature DB >> 23291588

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Ludmila Prokunina-Olsson1, Brian Muchmore, Wei Tang, Ruth M Pfeiffer, Heiyoung Park, Harold Dickensheets, Dianna Hergott, Patricia Porter-Gill, Adam Mumy, Indu Kohaar, Sabrina Chen, Nathan Brand, McAnthony Tarway, Luyang Liu, Faruk Sheikh, Jacquie Astemborski, Herbert L Bonkovsky, Brian R Edlin, Charles D Howell, Timothy R Morgan, David L Thomas, Barbara Rehermann, Raymond P Donnelly, Thomas R O'Brien.   

Abstract

Chronic infection with hepatitis C virus (HCV) is a common cause of liver cirrhosis and cancer. We performed RNA sequencing in primary human hepatocytes activated with synthetic double-stranded RNA to mimic HCV infection. Upstream of IFNL3 (IL28B) on chromosome 19q13.13, we discovered a new transiently induced region that harbors a dinucleotide variant ss469415590 (TT or ΔG), which is in high linkage disequilibrium with rs12979860, a genetic marker strongly associated with HCV clearance. ss469415590[ΔG] is a frameshift variant that creates a novel gene, designated IFNL4, encoding the interferon-λ4 protein (IFNL4), which is moderately similar to IFNL3. Compared to rs12979860, ss469415590 is more strongly associated with HCV clearance in individuals of African ancestry, although it provides comparable information in Europeans and Asians. Transient overexpression of IFNL4 in a hepatoma cell line induced STAT1 and STAT2 phosphorylation and the expression of interferon-stimulated genes. Our findings provide new insights into the genetic regulation of HCV clearance and its clinical management.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291588      PMCID: PMC3793390          DOI: 10.1038/ng.2521

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  56 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 2.  Messenger RNA regulation: to translate or to degrade.

Authors:  Ann-Bin Shyu; Miles F Wilkinson; Ambro van Hoof
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

Review 3.  Hepatitis in 2010: the dawn of a new era in HCV therapy.

Authors:  Sandra Ciesek; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

4.  Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.

Authors:  Svetlana Marukian; Linda Andrus; Timothy P Sheahan; Christopher T Jones; Edgar D Charles; Alexander Ploss; Charles M Rice; Lynn B Dustin
Journal:  Hepatology       Date:  2011-12       Impact factor: 17.425

Review 5.  CCL5: a double-edged sword in host defense against the hepatitis C virus.

Authors:  Antonios Katsounas; Joerg F Schlaak; Richard A Lempicki
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

6.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

7.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Authors:  Andrew J Muir; Mitchell L Shiffman; Atif Zaman; Boris Yoffe; Andrew de la Torre; Steven Flamm; Stuart C Gordon; Paul Marotta; John M Vierling; Juan Carlos Lopez-Talavera; Kelly Byrnes-Blake; David Fontana; Jeremy Freeman; Todd Gray; Diana Hausman; Naomi N Hunder; Eric Lawitz
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

8.  Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.

Authors:  Janett Fischer; Stephan Böhm; Markus Scholz; Tobias Müller; Heiko Witt; Jacob George; Christoph Sarrazin; Simone Susser; Eckart Schott; Vijayaprakash Suppiah; David R Booth; Graeme J Stewart; Florian van Bömmel; Annika Brodzinski; Balazs Fülöp; Pascal Migaud; Thomas Berg
Journal:  Hepatology       Date:  2012-04-18       Impact factor: 17.425

9.  Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression.

Authors:  H L Dickensheets; C Venkataraman; U Schindler; R P Donnelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

10.  ENCODE whole-genome data in the UCSC Genome Browser: update 2012.

Authors:  Kate R Rosenbloom; Timothy R Dreszer; Jeffrey C Long; Venkat S Malladi; Cricket A Sloan; Brian J Raney; Melissa S Cline; Donna Karolchik; Galt P Barber; Hiram Clawson; Mark Diekhans; Pauline A Fujita; Mary Goldman; Robert C Gravell; Rachel A Harte; Angie S Hinrichs; Vanessa M Kirkup; Robert M Kuhn; Katrina Learned; Morgan Maddren; Laurence R Meyer; Andy Pohl; Brooke Rhead; Matthew C Wong; Ann S Zweig; David Haussler; W James Kent
Journal:  Nucleic Acids Res       Date:  2011-11-09       Impact factor: 16.971

View more
  414 in total

Review 1.  Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Authors:  Tzu-Hao Lee; Hans L Tillmann; Keyur Patel
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

2.  Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?

Authors:  Tatsuo Kanda; Shingo Nakamoto; Osamu Yokosuka
Journal:  World J Virol       Date:  2015-08-12

3.  Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection.

Authors:  K Lind; E Svedin; R Utorova; V M Stone; M Flodström-Tullberg
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

4.  Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.

Authors:  Timothy Sheahan; Naoko Imanaka; Svetlana Marukian; Marcus Dorner; Peng Liu; Alexander Ploss; Charles M Rice
Journal:  Cell Host Microbe       Date:  2014-02-12       Impact factor: 21.023

Review 5.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

Review 6.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

7.  The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.

Authors:  Wenyu Lin; Chuanlong Zhu; Jian Hong; Lei Zhao; Nikolaus Jilg; Dahlene N Fusco; Esperance A Schaefer; Cynthia Brisac; Xiao Liu; Lee F Peng; Qikai Xu; Raymond T Chung
Journal:  J Hepatol       Date:  2014-12-03       Impact factor: 25.083

8.  SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo.

Authors:  Tanja Blumer; Mairene Coto-Llerena; Francois H T Duong; Markus H Heim
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

Review 9.  Murine models of hepatitis C: what can we look forward to?

Authors:  Markus von Schaewen; Alexander Ploss
Journal:  Antiviral Res       Date:  2014-01-24       Impact factor: 5.970

10.  Comparison of approaches for incorporating new information into existing risk prediction models.

Authors:  Sonja Grill; Donna P Ankerst; Mitchell H Gail; Nilanjan Chatterjee; Ruth M Pfeiffer
Journal:  Stat Med       Date:  2016-12-11       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.